Peptide Intelligence · GLP-1
Liraglutide
Also: Saxenda, Victoza
A daily-injected GLP-1 receptor agonist, the first in its class approved for weight management.
Approval status
FDA-approved
Type 2 diabetes (Victoza); chronic weight management (Saxenda). Generic liraglutide is available.
Compounding status
Approved product · compounded versions are unapproved
Included in FDA's Apr 30 2026 proposal to exclude GLP-1s from the 503B bulks list.
Evidence grade
A · Human randomized trials
SCALE trials. Jensen et al. (JAMA Netw Open 2024) found exercise plus liraglutide preserved hip and spine bone density better than liraglutide alone.
Known risks and label warnings
- Boxed warning: thyroid C-cell tumors; MTC/MEN 2 contraindication
- Pancreatitis; gallbladder disease; hypoglycemia with insulin/sulfonylureas; kidney injury from dehydration
Interactions people ask about
- Insulin and sulfonylureas
What people often measure
Framed as things to discuss with your clinician, not a protocol.
- Weight and lean mass
- Bone density context for older adults and postmenopausal women
- GI tolerance
Questions for your clinician
- Is a bone-density baseline appropriate for me?
- How do I combine exercise with this medication safely?
Get the full report by email
- The Liraglutide status card, monitoring list and clinician questions, printable
- The pre-therapy baseline checklist: what people commonly measure before starting any injectable
- A note the next time FDA or HHS acts on this compound
Wellness guidance only, not medical advice. We never sell or dispense medication.
Regulatory timeline for Liraglutide
2026-04-30
FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list
The proposal would end outsourcing-facility compounding of the three GLP-1s from bulk substance. Comments closed Jun 29 2026. If finalized, many compounded-GLP-1 users will face a supply transition.
FDA press announcement2026-01-13
FDA requests removal of the suicidal-ideation warning from GLP-1 labels
After review, FDA asked manufacturers to remove the suicidal behavior and ideation warning from Wegovy, Saxenda and Zepbound labels. Ozempic never carried it.
FDA Drug Safety Communication
Sources and review
Status as of 2026-09-02. Reviewed 2026-09-02 by Curtis Holder (product); clinical review pending; next review due 2026-12-01. Regulatory status changes; we update this page after each FDA or HHS action. Wellness guidance only, not medical advice. Med.xyz does not sell, prescribe or recommend any compound.